Hormone-Dependent Aging Problems in Women

키워드

참고문헌 (82)

1. Miquel J, "Menopause: a review on the role of oxygen stress and favorable effects of dietary antioxidants", Arch Gerontol Geriatr, 42, pp.289~306 (2006)
2. Amin SH, "Comprehensive evaluation of the older woman", Mayo Clin Proc, 78, pp.1157~1185 (2003)
3. Mooradian AD, "Endocrinology in aging", Dis Mon, 34, pp.393~461 (1988)
4. Gruber CJ, "Current concepts in aesthetic endocrinology", Gynecol Endocrinol, 16, pp.431~441 (2002)
5. Applegate WB, "Instruments for the functional assessment of older patients", N Engl J Med, 322, pp.1207~1214 (1990)
6. Park HM, "The HRT Awareness and Acceptance in Korean Postmenopausal Women: Results of Korean Gallup Epidemiologic Survey on Menopause and HRT", J Korean Soc Menopause, 8, pp.3~18 (2002)
7. Wasnich RD, "Vertebral fracture epidemiology", Bone, 18(3), pp.179S~183S (1996)
8. Messina M, "Skeletal benefits of soy isoflavones: a review of the clinical trial and epidemiologic data", Curr Opin Clin Nutr Metab Care, 7, pp.649~658 (2004)
9. North American Menopause Society, "Management of postmenopausal osteoporosis: position statement of the North American Menopause Society", Menopause, 9, pp.84~101 (2002)
10. Genazzani AR, "Postmenopausal osteoporosis: therapeutic options", Climacteric, 8, pp.99~109 (2005)
11. Cauley JA, "Women's Health Initiative Investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial", JAMA, 290, pp.1729~1738 (2003)
12. Anderson GL, "Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial", JAMA, 291, pp.1701~1712 (2004)
13. Rossouw JE, "Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial", JAMA, 288, pp.321~333 (2002)
14. Riggs BL, "Selective estrogen-receptor modulators-mechanisms of action and application to clinical practice", N Engl J Med, 348, pp.618~629 (2003)
15. Reginster JY, "Raloxifene reduces fractures in postmenopausal women with osteoporosis", Clin Orthop Relat Res, 443, pp.48~54 (2006)
16. Gennari L, "Lasofoxifene: a third-generation selective estrogen receptor modulator for the prevention and treatment of osteoporosis", Expert Opin Investig Drugs, 15, pp.1091~1103 (2006)
17. Gennari L, "Lasofoxifene: a new type of selective estrogen receptor modulator for the treatment of osteoporosis", Drugs Today (Barc), 42, pp.355~367 (2006)
18. Jorm AF, "The prevalence of dementia: a quantitative integration of the literature", Acta Psychiatr Scand, 76, pp.465~479 (1987)
19. Kokmen E, "Epidemiology of dementia in Rochester, Minnesota", Mayo Clin Proc, 71, pp.275~282 (1996)
20. Hagnell O, "Incidence of dementia in the Lundby Study", Neuroepidemiology, 11(1), pp.61~66 (1992)
21. Shughrue PJ, "Comparative distribution of estrogen receptor-alpha and -beta mRNA in the rat central nervous system", J Comp Neurol, 388, pp.507~525 (1997)
22. Toran-Allerand CD, "Estrogen as a treatment for Alzheimer disease", JAMA, 284, pp.307~308 (2000)
23. Alkayed NJ, "Neuroprotective effects of female gonadal steroids in reproductively senescent female rats", Stroke, 31, pp.161~168 (2000)
24. Goodman Y, "Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid beta- peptide toxicity in hippocampal neurons", J Neurochem, 66, pp.1836~1844 (1996)
25. Brinton RD, "17 beta- estradiol enhances the outgrowth and survival of neocortical neurons in culture", Neurochem Res, 22, pp.1339~1351 (1997)
26. Foy MR, "Estrogen and neural plasticity", Curr Dir Psychol Sci, 9, pp.148~152 (2000)
27. Ohkura T, "Estrogen increases cerebral and cerebellar blood flows in postmenopausal women", Menopause, 2, pp.13~18 (1995)
28. Bishop J, "Estradiol enhances brain glucose uptake in ovariectomized rats", Brain Res Bull, 36, pp.315~320 (1995)
29. Petanceska SS, "Ovariectomy and 17 beta-estradiol modulate the levels of Alzheimer's amyloid beta peptides in brain", Neurology, 54, pp.2212~2217 (2000)
30. Paganini-Hill A, "Estrogen deficiency and risk of Alzheimer's disease in women", Am J Epidemiol, 140, pp.256~261 (1994)
31. Brenner DE, "Postmenopausal estrogen replacement therapy and the risk of Alzheimer’s disease: a population-based case-control study", Am J Epidemiol, 140, pp.262~267 (1994)
32. Paganini-Hill A, "Estrogen replacement therapy and risk of Alzheimer disease", Arch Intern Med, 156, pp.2213~2217 (1996)
33. Waring SC, "Postmenopausal estrogen replacement therapy and risk of AD: a population- based study", Neurology, 52, pp.965~970 (1999)
34. Tang MX, "Effect of oestrogen during menopause on risk and age at onset of Alzheimer’s disease", Lancet, 348, pp.429~432 (1996)
35. Kawas C, "A prospective study of estrogen replacement therapy and the risk of developing Alzheimer’s disease: the Baltimore Longitudinal Study of Aging", Neurology, 48, pp.1517~1521 (1997)
36. Doraiswamy PM, "The Alzheimer's Disease Assessment Scale: patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials", Neurology, 48, pp.1511~1517 (1997)
37. Henderson VW, "Cognitive skills associated with estrogen replacement in women with Alzheimer's disease", Psychoneuroendocrinology, 21, pp.421~430 (1996)
38. Henderson VW, "Estrogen-containing hormone therapy and Alzheimer’s disease risk: understanding discrepant inferences from observational and experimental research", Neuroscience, 138, pp.1031~1039 (2006)
39. Zec RF, "The effects of estrogen replacement therapy on neuropsychological functioning in postmenopausal women with and without dementia: a critical and theoretical review", Neuropsychol Rev, 12, pp.65~109 (2002)
40. Samsioe G, "Urogenital aging-a hidden problem", Am J Obstet Gynecol, 178, pp.S245~S249 (1998)
41. Lovatsis D, "The role of estrogen in female urinary incontinence and urogenital aging: a review", Ostomy Wound Manage, 44, pp.48~53 (1998)
42. Iosif S, "The frequency of disorders of the lower urinary tract, urinary incontinence in particular, as evaluated by a questionnaire survey in a gynecological health control population", Acta Obstet Gynecol Scand, 60, pp.71~76 (1981)
43. Parkes AS, "Some effects of oestrin on the menstrual cycle of baboon and macaques", J Anat, 65, pp.272~276 (1931)
44. Iosif CS, "Estrogen receptors in the human female lower urinary tract", Am J Obstet Gynecol, 141, pp.817~820 (1981)
45. Wilson PD, "Steroid hormone receptors in the female lower urinary tract", Urol Int, 39, pp.5~8 (1984)
46. McCallin PF, "A study of the changes in the cytology of the urinary sediment during the menstrual cycle and pregnancy", Am J Obstet Gynecol, 60, pp.64~74 (1950)
47. Ulmsten U, "Evaluation of the urethral mucosa before and after oestrogen treatment in postmenopausal women with a new sampling technique", Gynecol Obstet Invest, 24, pp.208~211 (1987)
48. Bergman A, "Changes in urethral cytology following estrogen administration", Gynecol Obstet Invest, 29, pp.211~213 (1990)
49. Fantl JA, "Urethral axis and sphincteric function", Am J Obstet Gynecol, 155, pp.554~558 (1986)
50. Fantl JA, "Estrogen therapy in the management of urinary incontinence in postmenopausal women: a meta analysis. First report of the Hormones and Urogenital Therapy Committee", Obstet Gynecol, 83, pp.12~18 (1994)
51. Kinn AC, "Estrogens and phenylpropanolamine in combination for stress urinary incontinence in postmenopausal women", Urology, 32, pp.273~280 (1988)
52. Rud T, "The effects of estrogens and gestagens on the urethral pressure profile in urinary continent and stress incontinent women", Acta Obstet Gynecol Scand, 59, pp.265~270 (1980)
53. Foidart JM, "Efficacy of sustained- release vaginal oestriol in alleviating urogenital and systemic climacteric complaints", Maturitas, 13, pp.99~1107 (1991)
54. Bai SW, "Relationship between urinary profile of the endogenous steroids and postmenopausal women with stress urinary incontinence", Neurourol Urodyn, 22, pp.198~205 (2003)
55. Jung BH, "Urinary profile of endogenous steroids in postmenopausal women with stress urinary incontinence", J Reprod Med, 46, pp.969~674 (2001)
56. Isles CG, "Relation between coronary risk and coronary mortality in women of the Renfrew and Paisley survey: comparison with men", Lancet, 339, pp.702~706 (1992)
57. Barrett-Connor E, "Estrogen and coronary heart disease in women", JAMA, 265, pp.1861~1867 (1991)
58. Rackley CE, "Hormones and coronary atherosclerosis in women", Endocrine, 24, pp.245~250 (2004)
59. Kannel WB, "Menopause and risk of cardiovascular disease: the Framingham study", Ann Intern Med, 85, pp.447~452 (1976)
60. van der Schouw YT, "Age at menopause as a risk factor for cardiovascular mortality", Lancet, 347, pp.714~718 (1996)
61. Joakimsen O, "Population-based study of age at menopause and ultrasound assessed carotid atherosclerosis: The Tromsø Study", J Clin Epidemiol, 53, pp.525~530 (2000)
62. Mikkeola TS, "Estrogen replacement therapy, atherosclerosis, and vascular function", Cardiovasc Res, 53, pp.605~619 (2002)
63. Canonico M, "Postmenopausal hormone therapy and cardiovascular disease: an overview of main findings", Maturitas, 54, pp.372~379 (2006)
64. Staren ED, "Hormone replacement therapy in postmenopausal women", Am J Surg, 188, pp.136~149 (2004)
65. Hillard TC, "The long-term risks and benefits of hormone replacement therapy", J Clin Pharm Ther, 16, pp.231~245 (1991)
66. Adams MR, "Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis", Arterioscler Thromb Vasc Biol, 17, pp.217~221 (1997)
67. Vickers MR, "WISDOM study team. The women’s international study of long-duration oestrogen after menopause (WISDOM): a randomised controlled tria", BMC Womens Health, 7, pp.2~ (2007)
68. Rossouw JE, "Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial", JAMA, 288, pp.321~333 (2002)
69. Hsia J, "Women's Health Initiative Investigators. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative", Arch Intern Med, 166, pp.357~365 (2006)
70. Li C, "Risk of stroke and hormone replacement therapy. A prospective cohort study", Maturitas, 20, pp.11~18 (2006)
71. Vickers MR, "Main morbidities recorded in the women’s international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women", BMJ, 335, pp.239~ (2007)
72. Rossouw JE, "Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause", JAMA, 297, pp.1465~1477 (2007)
73. Herrington DM, "Effects of estrogen replacement on the progression of coronary-artery atherosclerosis", N Engl J Med, 343, pp.522~529 (2000)
74. Hulley S, "Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen", progestin Replacement Study (HERS) Research Group, 1998, pp.280, 605~613
75. Raine-Fenning NJ, "Skin aging and menopause: implications for treatment", Am J Clin Dermatol, 4, pp.371~378 (2003)
76. Davidson MB, "The effect of aging on carbohydrate metabolism: a review of the English literature and a practical approach to the diagnosis of diabetes mellitus in the elderly", Metabolism, 28, pp.688~705 (1979)
77. Björntorp P, "The regulation of adipose tissue distribution in humans", Int J Obes Relat Metab Disord, 20, pp.291~302 (1996)
78. Stevenson JC, "Oral versus transdermal hormone replacement therapy", Int J Fertil Menopausal Stud, 38(1), pp.30~35 (1993)
79. Rubinacci A, "Effect of low-dose transdermal E2", NETA on the reduction of postmenopausal bone loss in women, 2003, pp.10, 241~249
80. Stevenson JC, "Randomized trial of effect of transdermal continuous combined hormone replacement therapy on cardiovascular risk markers", Br J Haematol, 124, pp.802~808 (2004)
81. Caufriez A, "Hormonal replacement therapy (HRT) in postmenopause: a reappraisal", Ann Endocrinol (Paris), 68, pp.241~250 (2007)
82. John SC, "Oral versus non-oral hormone replacement therapy: how important is the route of administration?", Ginekol Pol, 78, pp.514~520 (2007)

관련 논문AI추천